A groundbreaking clinical trial offers new hope for babies diagnosed with myelomeningocele, a severe birth defect where the spinal cord doesn’t close completely during pregnancy. Researchers have reported promising results from a first-in-human study evaluating the safety and feasibility of using cellular therapy—specifically, allogeneic, live stem cells—to potentially repair the condition in utero. The therapy, assessed in the CuRe Trial, showed no cell-related adverse effects, paving the way for a larger phase 1/2a trial with 35 patients.
Myelomeningocele affects approximately 1,500 to 2,000 babies born in the United States each year, according to the Centers for Disease Control and Prevention . The condition can lead to a range of lifelong disabilities, including paralysis, bowel and bladder control issues and hydrocephalus. Current treatment typically involves surgery after birth to close the opening in the spine, but this doesn’t restore lost function.
What is Cellular Therapy for Myelomeningocele?
The CuRe Trial explores a different approach: repairing the defect before birth using cells with regenerative potential. The therapy utilizes allogeneic adipose tissue-derived mesenchymal stem cell clusters (ADMSCCs), meaning the cells are sourced from a donor rather than the patient themselves. These cells are injected into the fetal spine, with the goal of promoting tissue repair and potentially improving neurological outcomes. The initial phase 1 study focused on determining whether the therapy was safe and could be administered effectively.
Researchers assessed safety by monitoring for adverse events and dose-limiting toxicities. The study found that the ADMSCCs were well-tolerated, with no serious adverse events observed. This positive safety profile is a critical step forward, as it allows researchers to proceed with evaluating the therapy’s effectiveness.
Phase 1 Results and Next Steps
The initial phase 1 trial involved 20 patients, as reported in publications from March 2025 and August 30, 2025 . While the primary focus was safety, researchers as well looked at early indicators of efficacy, such as pain intensity, walking distance, and ulcer size. Significant reductions in ischemic pain and increases in pain-free walking distance were noted at 4, 12, and 24 weeks. Although ankle-brachial index and toe-brachial index showed no significant changes, ulcer healing was observed in one participant.
Based on these encouraging results, the trial is now moving into a phase 1/2a stage, with plans to enroll 35 patients in a non-staggered manner. This means that enrollment will proceed sequentially, rather than in groups, allowing researchers to closely monitor safety and efficacy as the trial progresses. The expanded trial will provide more robust data on the potential benefits of this innovative therapy.
The Role of S.Biomedics Co., Ltd.
The development of this ADMSCC therapy is being spearheaded by S.Biomedics Co., Ltd., a Seoul-based biotechnology company. The Phase 1/2a trial is funded by S.Biomedics, highlighting the company’s commitment to advancing cellular therapies for challenging medical conditions. The research team includes Yong-Man Park, Joon-Kee Park, Hyo-Shin Kim, Shin-Seok Yang, Jong-Wan Kim, and Dong-Ik Kim, all affiliated with Samsung Medical Center and Sungkyunkwan University School of Medicine in Seoul, Korea.
Challenges and Future Directions
While the initial results are promising, researchers emphasize that further studies are needed to confirm these findings and explore how this therapy might best be integrated with existing treatments. Larger, randomized controlled trials are essential to definitively determine the efficacy of ADMSCC therapy for myelomeningocele. The team also plans to investigate the optimal timing of treatment during pregnancy and the long-term effects of the therapy on neurological development.
The potential for in utero repair of myelomeningocele represents a significant advancement in the field of fetal surgery and regenerative medicine. If successful, this approach could dramatically improve the lives of children born with this debilitating condition. The ongoing CuRe Trial is a crucial step towards realizing that potential.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The next update from the CuRe Trial is expected in late 2026, following the completion of patient enrollment in the phase 1/2a study. We will continue to follow this research and provide updates as they turn into available.
Have thoughts on this developing story? Share your comments below, and please share this article with your network.
